| DrugRepV_0353 | Azithromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | Ebola Zaire | NA | Survival assay | Increase | Approved | 27622822 |
| DrugRepV_0354 | Azithromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0355 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | Ebola Zaire | NA | Survival assay | Increase | Approved | 27622822 |
| DrugRepV_0356 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0357 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | Ebola virus | Ebola Zaire | NA | Survival assay | Increase | Approved | 27622822 |
| DrugRepV_0358 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0359 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0360 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0361 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0362 | Benztropine | Nervous System | Parkinson disease | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0363 | Benztropine | Nervous System | Parkinson disease | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0364 | Chlortetracycline | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0365 | Chlortetracycline | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | Ebola Zaire | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0366 | Azithromycin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | Ebola Mayinga | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0367 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | Ebola Mayinga | NA | Survival assay | No significant effect | Approved | 27622822 |
| DrugRepV_0507 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | ma-EBOV | NA | Survival assay | Increase | Approved, Withdrawn | 26041706 |
| DrugRepV_0508 | Sertraline | Nervous System | Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder | Ebola virus | ma-EBOV | NA | Survival assay | Increase | Approved | 26041706 |
| DrugRepV_0753 | Favipiravir | Antiviral | Influenza virus | Nipah virus | NiV-Malaysia | NA | Survival assay | Increase | Investigational | 29765101 |
| DrugRepV_1610 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Survival assay | No significant effect | Approved, Investigational | 26217313 |
| DrugRepV_2111 | NITD008 | Antiviral | NA | Zika virus | GZ01/2016 | NA | Survival assay | Increase | NA | 27747251 |
| DrugRepV_2127 | Sofosbuvir | Antiinfectives For Systemic Use | Hepatitis C virus | Acquired immunodeficiency syndrome | Zika virus | Dakar/41519 | NA | Survival assay | Increase | Approved | 27902933 |
| DrugRepV_2138 | 7-deaza-2-C-methyl-D-adenosine | NA | Viral infection | Zika virus | MR766 | NA | Survival assay | Increase | NA | 27163257 |
| DrugRepV_3257 | Favipiravir | Antiviral | Influenza virus | Chikungunya virus | CHIKV S27 | NA | Survival assay | NA | Investigational | 24951535 |
| DrugRepV_3258 | Favipiravir | Antiviral | Influenza virus | Chikungunya virus | CHIKV S27 | NA | Survival assay | NA | Investigational | 24951535 |
| DrugRepV_3311 | TIvozanib | NA | Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease | Chikungunya virus | C21 | NA | Survival assay | NA | Investigational | 27177310 |
| DrugRepV_3355 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | RB1/H1N1pdm09 |  | Survival assay | Decrease | Approved | 29990517 |
| DrugRepV_3359 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/PR/8/34 | | Survival assay | Increase | Approved | 30028133 |
| DrugRepV_3456 | Zanamivir-Clarithromycin | Combinational | NA | Influenza virus | pdm09 | | Survival assay | Increase | NA | 29736671 |
| DrugRepV_3457 | Zanamivir-Flufenamic Acid-Clarithromycin | Combinational | NA | Influenza virus | pdm09 | | Survival assay | Increase | NA | 29736671 |
| DrugRepV_3548 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Shanghai/4664T/2013(H7N9) | | Survival assay | Increase | Approved | 30459739 |
| DrugRepV_3549 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Shanghai/4664T/2013(H7N9) | | Survival assay | Increase | Approved | 30459739 |
| DrugRepV_3556 | Sofosbuvir | Antiinfectives For Systemic Use | Hepatitis C virus | Acquired immunodeficiency syndrome | Chikungunya virus | Asian strain | NA | Survival assay | Increase | Approved | 30455237 |
| DrugRepV_4317 | Carbocyclic 3-deazaadenosine | NA | NA | Ebola virus | EBO-Z | NA | Survival assay | Increase | NA | 9988190 |
| DrugRepV_4320 | FGI-106 | NA | NA | Ebola virus | Zaire | NA | Survival assay | Increase | NA | 19523489 |
| DrugRepV_4630 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | No significant effect | Approved | 19853271 |
| DrugRepV_4631 | Ampligen | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | Increase | NA | 19853271 |
| DrugRepV_4632 | UDA | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | Increase | NA | 19853271 |
| DrugRepV_4633 | Cremaphor | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | No significant effect | NA | 19853271 |
| DrugRepV_5074 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Survival assay | Increase | Investigational | 29936152 |
| DrugRepV_5075 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Survival assay | Increase | Investigational | 29936152 |
| DrugRepV_5078 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Survival assay | No significant effect | Approved | 29936152 |
| DrugRepV_5079 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Survival assay | No significant effect | Approved | 29936152 |
| DrugRepV_5170 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | ZH501 | NA | Survival assay | Increase | Approved, Investigational | 28442428 |
| DrugRepV_5206 | Favipiravir | Antiviral | Influenza virus | Rift Valley fever virus | ZH501 | NA | Survival assay | Increase | Investigational | 24722586 |
| DrugRepV_5271 | Favipiravir | Antiviral | Influenza virus | Lassa virus | Josiah | NA | Survival assay | Increase | Investigational | 26456301 |
| DrugRepV_5272 | Favipiravir | Antiviral | Influenza virus | Lassa virus | Josiah | NA | Survival assay | Increase | Investigational | 26456301 |
| DrugRepV_5709 | Sunitinib-Erlotinib | NA | NA | Dengue virus | NA | | Survival assay | Increase | NA | 29753658 |
| DrugRepV_5938 | Prochlorperazine Dimaleate | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5939 | Prochlorperazine Dimaleate | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5940 | Prochlorperazine Dimaleate | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5941 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5942 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5943 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5944 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5945 | Prochlorperazine Novamin | Nervous System | Nausea | Vomiting | Schizophrenia | Dengue virus | New Guinea C | | Survival assay | Increase | Approved | 25028694 |
| DrugRepV_5965 | NITD008 | Antiviral | NA | Dengue virus | D2S10 | | Survival assay | Increase | NA | 19918064 |
| DrugRepV_5989 | Celgosivir | Antiviral | Hepatitis C virus | Dengue virus | S221 | | Survival assay | Decrease | Phase II | 22867971 |
| DrugRepV_6157 | Schisandrin A | NA | NA | Dengue virus | NA | | Survival assay | Decrease | NA | 28338050 |
| DrugRepV_6192 | Bromocriptine | Nervous System | Parkinson disease | Dengue virus | 09--48 | | Survival assay | No significant effect | Approved | 27181378 |
| DrugRepV_7054 | Manidipine | Cardiovascular agents | Hypertension | Japanese encephalitis virus | AT31 | | Survival assay | No significant effect | Approved, Investigational | 28814523 |
| DrugRepV_7093 | Castanospermine | Antiviral | Dengue and Parainfluenza | West Nile virus | NY 1999-Replicon | | Survival assay | Increase | Experimental | 15994763 |
| DrugRepV_7094 | Castanospermine | Antiviral | Dengue and Parainfluenza | West Nile virus | NY 1999-Replicon | | Survival assay | No significant difference | Experimental | 15994763 |
| DrugRepV_7113 | N-nonyl-deoxynojirimycin | NA | NA | Japanese encephalitis virus | RP-9 | | Survival assay | Increase | NA | 11907199 |
| DrugRepV_7114 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Japanese encephalitis virus | P3 | | Survival assay | Increase | Approved | 30567313 |
| DrugRepV_7350 | Indirubin | NA | NA | Japanese encephalitis virus | Beijing-1 | | Survival assay | Increase | Investigational | 22911608 |
| DrugRepV_7351 | NG-monomethyl-L-arginine | NA | Obesity | Type 2 Diabetes | Ocular Physiology | Regional Blood Flow | Japanese encephalitis virus | 78668A | | Survival assay | Decrease | Approved, Investigational | 10762444 |
| DrugRepV_7352 | N-nitro-L-arginine methyl ester | NA | NA | Japanese encephalitis virus | RP-9 | | Survival assay | Decrease | NA | 9188590 |